Tourette’s Syndrome (TSG) is a neuropsychiatric disorder with motor and vocal tics and psychiatric comorbidities, including Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive-Compulsive Behavioural Disorder (OCD).
Based on anecdotal reports and preliminary controlled studies. It suggests that cannabis-based medicine (CBM) may improve tics and comorbidities in adults with DWG. According to one survey, patients with Tourette’s syndrome prefer medical cannabis to pure THC and Sativex
Published in early 2020, this study is available by clicking on this link. It carried out at the Medical Faculty of Hannover, Germany, and at the Medical University of Warsaw, Poland.
This study designed to further investigate the efficacy and safety of medical cannabis in Tourette’s syndrome. And specifically to compare the effects of different forms of medical cannabis.
First, the researchers conducted a retrospective analysis of the data. Including all adult patients who had used medical cannabis for the treatment of GTS at some point in time. All of these patients invited to complete an online survey (the second part of the study) to receive more detailed data on cannabis treatment.
From medical records, they identified 98 patients who had used medical cannabis (most often street cannabis followed by nabiximols, dronabinol, medicinal cannabis) for the treatment of Tourette’s syndrome :
Of the 38 patients who were able to judge,
66% preferred drug treatment with cannabis.
5% street cannabis
Generally, medical cannabis has resulted in subjective improvement of tics (about 60% in 85% of treated cases). Comorbidities (55% of treated cases, most often OCB / OCD, ADHD and sleep disorders) and quality of life (93%).
The effects of medical cannabis appear to persist over the long term. Adverse events occurred in half of the patients but considered tolerable. The doses of all medical cannabis used varied considerably.
Patients considered cannabis (with a preference for strains rich in tetrahydrocannabinol [THC]) to be more effective and better tolerated than nabiximols and dronabinol. These data confirmed by the results of the online survey.
Based on the results, the researchers write that it is further confirmed that medical cannabis may be effective and safe in the treatment of tics and co-morbidities in at least a subgroup of adult patients with Tourette’s syndrome.
So , in this sample, patients preferred THC-rich cannabis over dronabinol and nabiximols, which may be related to the entourage effect of cannabis. However, several limitations of the study need consideration, such as the uncontrolled open design and retrospective analysis of the data.